How the Evolution of Immunotherapy Will Impact Oncology Nurses
Immunotherapy is one of the fastest-evolving areas of oncology to date. Previously, it could take years for some cancers to see new treatment options; today, the U.S. Food and Drug Administration is approving new immuno-oncology agents or new indications for those agents every few weeks. It’s a boon and a challenge to medical professionals. On the one hand, potentially life-changing treatments are making way to patients who need them—patients who have exhausted first-line treatments and now have limited options. On the other hand, healthcare professionals may struggle to stay current with the emerging trends, cutting-edge science, and evolving treatment plans for their patients.
FDA Approves Midostaurin for FLT3-Positive Adult AML, Advanced Systemic Mastocytosis
On April 28, 2017, the U.S. Food and Drug Administration (FDA) approved midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
FDA Issues Warnings to Fraudulent Cancer Treatment Companies
On April 25, 2017, the U.S. Food and Drug Administration (FDA) issued warning letters to 14 companies that were selling fraudulently marketed products claiming to prevent, diagnose, treat, or cure cancer. In total, the companies produced more than 65 products that have been sold in the United States without FDA approval.
FDA Approves Nivolumab for Advanced or Metastatic Bladder Cancer
On February 2, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy.
Combination Therapy Shows Promise for Chronic Myeloid Leukemia
According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia.
FDA Approves Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
FDA Approves Pembrolizumab for Treatment of Non-Small Cell Lung Cancer
Sentinel Node Dissection Sufficient for Localized Breast Cancer
FDA Approves Olaratumab for Soft Tissue Sarcoma
FDA Approves Atezolizumab for Advanced Non-Small Cell Lung Cancer
FDA Modifies Use of Erlotinib in NSCLC, Used Only in Patients With EGFR Tumor Mutations
Is Scalp Cooling the Right Decision for Your Patients?
Inotuzumab Ozogamicin May Improve Survival in ALL
Does the Sequence of Chemotherapy and Biotherapy Agents Matter?
Poliovirus May Be Key to Treating Glioblastoma
Pembrolizumab Associated With Long-Term Survival in Advanced Melanoma
FDA Approves Pembrolizumab for Head and Neck Squamous Cell Carcinoma
Radiotherapy Optimizes Outcomes and Quality of Life Through Interdisciplinary Care
FDA Offers Expanded Access to Patients in Need of Treatment
FDA Allows Marketing for First Nucleic Acid-Based Quantitation Test for Use During Treatment CML
CDC Advises Against Using Oral Liquid Docusate
Promote Cancer Prevention in the Face of Cancer Treatment
Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects
Radiation Plus Chemotherapy Improves Survival From Low-Grade Gliomas
Proteins Targeting Tumor Microenviroment May Block Metastatic Ovarian Cancer Growth
FDA Approves Atezolizumab in Advanced or Metastatic Urothelial Carcinoma
Low-Dose Metformin May Reduce Risk of Colorectal Adenomas
New Treatment Approach May Be Effective for Aggressive Ovarian Cancer
FDA Approves Venetoclax for CLL
FDA Approves Defibrotide Sodium for Hepatic Veno-Occlusive Disease
FDA Approves Crizotinib for ROS1-Positive Lung Cancer
FDA Approves New Indication for Everolimus
FDA Approves New Indication for Obinutuzumab
On February 26, 2016, the U. S. Food and Drug Administration approved obinutuzumab (Gazyva® Injection, Genentech, Inc.) for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. Obinutuzumab was previously approved for use in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia.